Searchable abstracts of presentations at key conferences in endocrinology

ea0004p50 | Endocrine tumours and neoplasia | SFE2002

No activating point mutation in Cyclin-Dependent Kinase 4 (CDK4) in pituitary adenomas, insulinomas and Leydig cell tumours

Bibi R , Diaz-Cano S , Vax V , Gueorguiev M , Kola B , Bressac B , Walker G , Grossman A , Korbonits M

BACKGROUND: Cell cycle dysregulation is one of the defining features of cancer. Cyclin-dependent kinase 4 (CDK4), together with its regulatory subunit Cyclin D, governs cell cycle progression in G1 phase. CDK4 is in turn regulated by cyclin-dependent kinase inhibitors, including p16INK4A (CDKN2A). Dysregulation of the INK4A/CDK4/cyclin D complex has been established in different a variety of types of human tumours. Dominant mutations affecting codon 24 of the CDK4 gene (replac...